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1. Introduction 
Tumor protein 53 (Tp53 or p53) continued to be a subject of 
active research since its first identification in the late 1970s.1-10 
The protein p53 first thought to be an oncoprotein has eventually 
emerged as a tumor suppressor playing central role in the 
maintenance of genome stability.1,11 In unstressed cells, the 
negative regulator human double minute 2 (HDM2) protein 
polyubiquitinates p53 leading to its continuous proteosomal 
degradation, therefore, keeping p53 concentration at a low 
level.12-14 Whereas, upon cell stress or DNA damage, p53 gets 
activated via disruption of the p53-HDM2 interaction, which 
results in accumulation of p53 leading to inhibition of cell growth 
and apoptosis.12-14 In many human cancer cells p53 behaves 
incorrectly with up to 50% of tumors containing cells possessing 
p53 mutations.11 Furthermore, cancer-inducing viruses can 
inactivate p53, for example, E6 protein of human papilloma virus 
(HPV) induces p53 degradation.15  
The protein p53 consists of five major domains, such as 
transactivation domain (TAD), proline-rich domain, DNA 
binding core domain, tetramerization domain and regulatory 
domain.13 The N-terminal TAD is acidic, intrinsically disordered 
and responsible for binding to various transcription factors.13 The 
activity of p53 is controlled by its interaction with HDM2 and 
transcriptional co-activators CREB-binding protein (CBP) and 
p300.14 The TAD of p53 has binding sites to interact with 
transcription adaptor putative zinc finger 1 (TAZ1), TAZ2, 
kinase-inducible domain (KID) interacting domain (KIX), and 
nuclear receptor co-activator binding domain (NCBD) of CBP or 
p300 along with the p53-binding domain of HDM2.14 TAD-p53 
interacts via its two active regions AD1 (1-42) and AD2 (43-63).2 
In the unstressed cells, AD2 binds to CBP domains while AD1 
binds to HDM2.14 Thus, through AD1 and AD2, TAD forms a 
ternary complex that leads to the degradation of p53 by 
ubiquitination.14 On the other hand, genotoxic stress results in the 
phosphorylation at Thr and Ser residues of AD1 which severely 
weakens its interaction with HDM2,14 which leads to preferential 
binding of TAD to the CBP domains and activation of p53.13,14  
There are not many proteins in molecular oncology that have 
so many sites for post-translational modifications (PTMs) as 
p53.16 Importantly, the tumor suppressor p53 was shown to be a 
phosphoprotein just after few years after its discovery.17,18 Thus, 
phosphorylation turned into the most recognized PTM and was 
extensively studied over the years.3 The TAD alone contains 
seven Ser and two Thr residues available for phophorylation.14 A 
single phosphorylation at Thr18 results in two-times increase of 
p53 affinity towards TAZ1 of CBP.14 A more significant 10-fold 
enhancement occurs when Ser15 and Ser20 are also 
phosphorylated along with Thr18.14 Studies by several authors 
have shown that individual phosphorylations of Ser15, Ser20, 
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Ser33, Ser37, Ser46, Thr18 and Thr55 modulate interactions of 
p53 to each of the four binding domains of CBP/p300 but to 
different extents.16,19,20 However, Thr18 has been found having 
the most potent influence.3,13,16 Moreover, it has been observed 
that depending on the type and intensity of the stress and cell 
type, differential phosphorylation and thereby fine modulation of 
p53-CBP/p300 interaction and transcriptional outcome occurs.3,16 
Thus, these events collectively provide a regulatory switch that 
facilitates TAD-p53 binding to CBP/p300 over its negative 
regulator HDM2.16 
Apart from phosphorylation, there are several acetylation sites 
in the C-terminal domains of p53 which are crucial for p53 to 
maintain its function. The lysine residues, Lys305, Lys370, 
Lys372, Lys373, Lys381, Lys382, and Lys386 are acetylated 
during different forms of genotoxic and non-genotoxic 
stress.16,21,22 Significance of acetylation lies in the fact that it is 
mutually exclusive to ubiquitination for p53 regulation.16 In 
unstressed cells ubiquitination leads to the degradation of p53 
while acetylation ensures non-ubiquitination of the p53 residues 
in stressed cells which leads to p53 stabilization. Thus, both 
phosphorylation and acetylation are critical factors for p53 
stabilization.16 
Although there are multiple studies that provided valuable 
insights into the role of phosphorylation of individual residues 
and other PTMs, there are still many questions that need to be 
addressed to fully understand the biological significance of p53. 
The TAD-p53 (wild-type or phosphorylated) used so far in most 
of the studies were either prepared biosynthetically or 
biologically expressed14 or in some cases a small part of it has 
been synthesized chemically.13 The efficient total chemical 
synthesis or semi-synthesis of full-length p53 would thus be 
particularly attractive to address the questions of the role of the 
combinations of PTMs in p53 function because such methods can 
allow for preparation of modified analogues with precise patterns 
of the desired modifications.23 Towards this goal, in this 
manuscript a detailed synthetic procedure for preparation of 
TAD-p53 is described based on the combination of Fmoc/tBu-
solid phase peptide synthesis (SPPS) and native chemical ligation 
(NCL), which complements previously published synthetic 
protocol.24 
2. Results and Discussion 
In this work the 61-residue transactivation domain of p53 
(TAD-p53) has been synthesized using a three peptide segment 
ligation strategy (Fig. 1). The peptides were joined by native 
chemical ligation (NCL) using unprotected peptide-αthioesters 
and Cys-containing peptide segments.25-29 The TAD-p53 has no 
native Cys residues in its sequence, therefore, Gln16 and Gln38 
were replaced by Cys residues in which the thiol side chains were 
alkylated using bromoacetamide to achieve a side chain 
chemically similar to glutamine. Another modification was made 
to prevent the problem of oxidation of the methionines, which 
was shown to complicate the synthesis and isolation.24 Thus, 
Met1, Met40 and Met44 were replaced with nearly isosteric 
norleucine (Nle) residues. As a result, the three segments in the 
synthesis were Nle1-Ser15 (segment-1), Cys16-Ser37 (segment-
2) and Cys38-Asp61 (segment-3) (Fig. 1). 
The ligation of three segments can be advantageous compared 
to previously reported synthesis based on a two-segment 
approach24 for the following reasons: (i) peptide segments needed 
for ligation are shorter and easier to synthesize; (ii) elucidation of 
the role of PTMs requires synthesis of protein libraries where the 
three-segment strategy is more modular and flexible. PTMs can 
occur along the entire sequence of TAD-p53.3 For this reason 
larger combinatorial diversity of the library will be easier to 
achieve with three-segment ligation approach, which will require 
lesser number of peptide building blocks. For example, to 
prepare all 512 possible phospho-variants of TAD-p53 (seven Ser 
and two Thr phosphorylation sites lead to 29 = 512 
combinations), it will require synthesis of 132 peptide segments 
(27+22) via a two-segment ligation strategy (approach in ref. 24) 
and only 28 peptide building blocks (23+24+22) using a three-
segment ligation method (Fig. 1). 
The ligation junctions (residues (15-16) and (37-38), 
respectively) were chosen in the regions of the sequence that 
remain unstructured in the known complex with nuclear co-
activator binding domain (NCBD) of CBP,2 therefore 
modification of Gln16 and Gln38 into pseudo-glutamines is 
unlikely to affect the properties of the synthetic TAD-p53.  
Both the C-to-N and N-to-C one-pot ligation strategies were 
tested in our study with different thioesters of the middle segment 
used in the N-to-C native chemical ligation and their comparative 
yields are presented in this article. 
2.1. Synthesis of the peptide segments 
For the synthesis of the segment-1 (Nle1-Ser15), manual 
conventional Fmoc/tBu-SPPS was applied using hydrazide resin 
and HBTU (hexafluorophosphate benzotriazole tetramethyl 
uronium) as coupling agent and N,N-diisopropylethylamine 
(DIEA) as activator base (details are in the Appendix A). 
Subsequent cleavage from the resin and HPLC purification 
resulted in a yield of 56%. Segment-1 (Nle1-Ser15)-αNHNH2 was 
then transformed into the corresponding αthioester (Fig. S1). To 
achieve such conversion, the C-terminal αhydrazide functional 
group was first oxidized to αazide by sodium nitrite and in situ 
thioesterified with MeSNa (sodium 2-mercaptoethanesulphonate) 
making it suitable for native chemical ligation.30 
Meanwhile, the middle segment-2 (Cys16-Ser37) was 
synthesized in two forms (see Table S1 and Fig. S2). In the first 
approach, using the hydrazide resin, (Cys16-Ser37)-αNHNH2 
(segment-2A) was synthesized using microwave-assisted SPPS 
using N,N′-diisopropylcarbodiimide (DIC) and Oxyma (2-cyano-
2-(hydroxyimino)acetic acid ethyl ester) as coupling reagents. 
After cleavage and HPLC purification the yield was found to be 
32%. Such (Cys16-Ser37)-αNHNH2 containing N-terminal Cys 
residue was used in N-to-C ligations.  
In another method, employed for C-to-N ligations, N-acylurea 
linker was used for the middle segment synthesis.31 In this 
process, a linker 3-amino-4-(methylamino)benzoic acid was 
prepared with the primary amino group Fmoc-protected.31 The 
Fmoc-Rink amide resin was used in this case and amino acid 
glycine was coupled to it followed by the linker and then the C-
terminal amino acids starting from Ser37 were coupled using 
Fmoc-SPPS. As required in this method the last coupled N-
terminal amino acid was Boc-Thz (Boc-thiazolidine).31 It has to 
be noted that in the synthesis of (Thz16-Ser37)-αMeNbz 
(segment-2B) a more efficient coupling reagent HATU 
(hexafluorophosphate azabenzotriazole tetramethyl uronium) 
needs to be used instead of HBTU in conjunction with double 
couplings of the five C-terminal residues to avoid deletions. The 
peptide was prepared at room temperature using Syro I automatic 


















































Fig. 1. Schematic representation of the N-to-C and C-to-N peptide ligation strategies for the total chemical synthesis of transactivation 

















Fig. 2. (a) One-pot native chemical ligation towards TAD-p53 in 
N-to-C direction (using MeSNa for preparing active thioester 
after first NCL) monitored by analytical HPLC. By-products in 
panel 6 (from the top) are (1) (Cys38-Asp61)-αamide, (2) (Nle1-
Ser15)-(Cys16-Ser37)-αOH, (3) (Nle1-Ser15)-(Cys38-Asp61)-
α
amide. (b) ESI-MS-Orbitrap analysis of the pure TAD p53. 
Multiple peaks for each charge state are due to Na+ and K+ ion 
adducts. A repeating of the synthesis (summarized in Fig. S4) 
using this procedure with several modifications (see Appendix A) 
confirms complications in N-to-C strategy. 
moiety (linker) was subjected to cyclization on resin using 
chloroformate derivative and DIEA base in successive steps to 
convert it into an N-acylurea (MeNbz) moiety.31 The peptide was 
cleaved and purified with a yield of 25% before MeSNa was used 
for thioesterification of (Thz16-Ser37)-αMeNbz by substituting 
the MeNbz moiety (Fig. S2). The resultant (Thz16-Ser37)-
αthioester building block was used for C-to-N ligations. 
The C-terminal (Cys38-Asp61)-αamide segment was 
synthesized on a Rink-amide resin using microwave-assisted 
SPPS using DIC and Oxyma with an isolated yield of 16%  




2.2. Native chemical ligation of peptide segments 
2.2.1. N-to-C one-pot and sequential ligations 
The two segments, (Nle1-Ser15)-αSR (MeSNa thioester) and 
(Cys16-Ser37)-αNHNH2 were ligated in a denaturing buffer (6 M 
guanidine-HCl, 200 mM phosphate, pH 7) within 3 h with a good 
conversion as evident from analytical HPLC (Fig. 2). 
Subsequently, (Nle1-Ser15)-(Cys16-Ser37)-αNHNH2 was 
converted to αthioester upon treatment with NaNO2 and in situ 
reaction with MeSNa furnishing the corresponding (Nle1-Ser15)-  
 (Cys16-Ser37)-αthioester ready for the second NCL with 
(Cys38-Asp61)-αamide segment. However, we found that the 
second NCL was complicated by hydrolysis of (Nle1-Ser15)-
(Cys16-Ser37)-αthioester. The reaction was continued for 
extended period of time (10 h) to reach maximum possible 
conversion. In Fig. 2 (6th panel from the top) the peaks 1, 2, 3 
correspond to unreacted (Cys38-Asp61)-αamide, (Nle1-Ser15)-
(Cys16-Ser37)-αOH and (Nle1-Ser15)-(Cys38-Asp61)-αamide, 
respectively, along with the desired (Nle1-Ser15)-(Cys16-Ser37)-
(Cys38-Asp61)-αamide product. High quantities of unreacted 
(Cys38-Asp61)-αamide are due to undesired depletion of (Nle1-
Ser15)-(Cys16-Ser37)-αthioester. The by-product 3 arises from 
the undesired ligation between (Nle1-Ser15)-αSR (remaining 
from the first ligation) and (Cys38-Asp61)-αamide, which is 
present in excess. 
The next step was the alkylation of the two Cys residues to 
convert them into pseudo-glutamines (ψ-Gln16 and ψ-Gln38). To 
achieve this, 1 M bromoacetamide was prepared in 6 M 
guanidine-HCl, 200 mM phosphate, pH 7 buffer and added to the 
reaction mixture in three-fold excess over total thiol amount in 
the solution and kept at 40 °C after adjusting the pH to 6.6. This 
reaction was fast and was stopped after 10 min since longer 
reaction times can result in undesirable alkylation of residues 
other than Cys. Reduction of pH to around 4 after the reaction 
prevents any undesired alkylation. Purification of the reaction 
mixture resulted in the final 61-residue TAD-p53 analogue in 
13% overall yield (based on the (Nle1-Ser16)-αSR).  
Instead of adding MeSNa to convert (Nle1-Ser15)-(Cys16-
Ser37)-αazide into the corresponding αthioester, ligation with 
(Cys38-Asp61)-αamide was also tried with 50 mM or 100 mM 
MPAA (4-mercaptophenylacetic acid) through in situ thioester 
generation and subsequent ligation but in each case large 
amounts of hydrolyzed (Nle1-Ser15)-(Cys16-Ser37)-αOH were 
observed concomitant with minute amounts of the ligation 
product with (Cys38-Asp61)-αamide segment (data not shown). It 
appears that activation in the form of aryl-thioester produces 
highly reactive peptide-αthioester particularly labile to hydrolysis. 
In the presence of a different alkyl-thiol such as 2-
(dimethylamino)ethanethiol hydrochloride used previously in 
NCL32 introduced for transforming (Nle1-Ser15)-(Cys16-Ser37)-
α
azide into a thioester (while maintaining the same concentrations 
and conditions as of MeSNa) the desired full length TAD-p53 
could be obtained in a 10% yield (based on (Nle1-Ser15)-αSR) 
which is similar to the results with MeSNa thiol (Fig. S5).  
The sequential three segment ligation in N-to-C direction 
rather than one-pot procedure was also attempted. In this case the 
product of the first ligation (Nle1-Ser15)-(Cys16-Ser37)-
αNHNH2 was alkylated using 2-bromoacetamide and converted 
into the corresponding αthioester followed by HPLC purification. 
Subsequently, second ligation was performed (see Fig. S6). After 
Cys alkylation and second HPLC purification, the desired 














than half of what was obtained from one-pot procedure because 
of losses in the additional HPLC purification. 
2.2.2. C-to-N one-pot ligation approach 
To improve the efficiency of the sequential native chemical 
ligations and reduce the amount of by-products arising from the 
hydrolysis observed in the N-to-C ligation approach, a reverse C-
to-N ligation route was adopted (Fig. 3). In this case the 
thioesterification of the middle segment was performed 
separately and unlike in N-to-C ligation the (Thz16-Ser37)-αSR 
(MeSNa thioester) segment was used as the starting peptide 
containing Thz (thiazolidine) moiety at the N-terminus instead of 
Cys, which is necessary to avoid undesired head-to-tail 
cyclization. Thus, (Thz16-Ser37)-αSR (MeSNa thioester) and 
(Cys38-Asp61)-αamide were ligated in 6 M guanidine-HCl, 200 
mM phosphate buffer at pH 6.8 (Fig. 3). Subsequently, the 
thiazolidine ring was cleaved by treatment with 0.2 M 
methoxyamine-HCl at pH 4. After thiazolidine deprotection, 
second ligation with (Nle1-Ser15)-αthioester segment was 
performed in the presence of 50 mM MPAA. The MPAA aryl-
thiol catalyst was used to increase the efficiency of the second 
ligation in the presence of an internal Cys residue.28 It took 4 h at 
40 °C for the reaction to reach near completion indicated by 
unchanged relative intensity of the analytical HPLC peaks  
(Fig. 3). Then, 2-bromoacetamide was used for alkylation similar 
to the procedure described earlier for N-to-C ligations. An overall 
yield of 26% was obtained after HPLC purification of the final 
peptide (based on (Cys38-Asp61)-αamide segment). 
 
Fig. 3. (a) One-pot native chemical ligation of three peptide 
segments in C-to-N direction monitored by analytical HPLC. (b) 
ESI-MS-Orbitrap analysis of the pure TAD-p53. 
2.3. Characterization of binding of chemically synthesized 
TAD-p53 to nuclear co-activator binding domain (NCBD) 
2.3.1. Circular dichroism study 
TAD-p53 is an intrinsically disorder protein domain, i.e. in 
isolated state it does not have well-defined secondary or tertiary 
structure.13 We confirmed that synthetic TAD-p53 is 
unstructured, which can be seen in its CD spectrum 
corresponding to a random coil (Fig. 4). Intrinsic disorder plays a 
key role in the biological function of p53 by providing structural 
plasticity and enabling this protein to bind to a variety of other 
proteins.33 In this way, p53 can serve as a hub in protein-protein 
interaction networks regulating gene expression.33 One of such 
interacting partners is nuclear co-activator binding domain 
(NCBD) of CREB-binding protein (CBP). We therefore 
inspected structural changes in synthetic TAD-p53 which occur 
upon interaction with NCBD by recording the CD spectra of 
TAD-p53/NCBD complex. We found that the helicity in the 
complex increases significantly (Fig. 4) compared to free TAD-
p53 or NCBD alone judged by the enhancement of ellipticity at 
222 nm. The presence of α-helices in the TAD-p53/NCBD 
complex is in accordance with previously reported NMR 
structure of the complex.2 Thus, the CD experiments confirm that 
the chemically synthesized TAD-p53 retains the characteristics of 
biologically expressed protein domain by forming a complex 
with NCBD.  
Fig. 4. Circular dichroism (CD) spectra of free TAD-p53, NCBD 
and their 1:1 complex in 20 mM phosphate buffer at pH 7.4 at 25 
°C (concentration of protein = 25 µM). 
2.3.2. NMR study 
In addition, 1D 1H NMR and 2D 1H-13C heteronuclear single 
quantum coherence (HSQC) spectroscopy were also used to 
monitor structural changes occurring upon binding of TAD-p53 
to NCBD (Fig. 5). Changes upon binding are clearly visible in 1H 
NMR corresponding to aromatic protons (spectra were recorded 
in D2O), where sharp resonances are present for free TAD-p53, 
which is in agreement with intrinsically disordered properties of 
this protein domain, whereas signals become broader upon 
addition of NCBD corresponding to a larger size of the complex 
and different environment of aromatic side-chains (Fig. 5a). The 
1H-13C HSQC is also supportive of complex formation: overlay 
of the methyl regions of the spectra for free TAD-p53 and its 
complex with NCBD show distinct resonances indicative of 
different chemical surroundings of the corresponding methyl 















Fig. 5. (a) Overlay of 1H NMR (aromatic region) and (b) 1H-13C 
HSQC (methyl region) spectra of free TAD-p53 (in blue) and 1:1 
complex with NCBD (in red) recorded in D2O. 
 
3. Conclusions 
In this article we reported total chemical synthesis of the  
(1-61)-form of transactivation domain (TAD) of p53 protein 
based on native chemical ligation of three peptide segments. The 
peptide building blocks are relatively short (less than 24 residues) 
and can be efficiently synthesized using Fmoc/tBu-SPPS 
approach accessible in many academic laboratories using 
commercially available building blocks. Two approaches, N-to-C 
and C-to-N have been used to ligate the peptide segments to 
achieve the full-length TAD-p53 and it has been found that C-to-
N approach results in 2- to 2.5-fold higher yield than N-to-C 
method. The non-canonical residues introduced in the sequence 
to facilitate the synthetic protocols such as three norleucines (at 
sites 1, 40 and 44) and two pseudo-glutamines (at sites 16 and 
38) do not affect coupled folding and binding to NCBD which is 
a known binding partner of p53. The reported synthetic approach 
based on the ligation of three segments will be particularly 
advantageous for the combinatorial synthesis of the post-
translationally modified variants of TAD-p53 (e.g. 
phosphorylated) in order to perform proteome-wide interaction 
profiling as a function of phosphorylation pattern using protein 
arrays and other approaches to study protein binding interactions. 
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